| Ticker: CAMH | 1 Oak Park Drive | |
| Exchange: NASDAQ-National Market | Bedford, Massachusetts 01730 | |
| Industry: Manufacturing | (617) 271-1200 |
| Type of Shares: | Common Shares | Filing Date: | 5/31/96 | |
| U.S. Shares: | 2,000,000 | Offer Date: | 8/2/96 | |
| Non-U.S. Shares: | 500,000 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,437,750 | Offer Price: | $9.00 | |
| Secondary Shares: | 62,250 | Gross Spread: | $0.63 | |
| Offering Amount: | $30,000,000 | Selling: | $0.32 | |
| Expenses: | $625,000 | Reallowance: | $0.10 | |
| Shares Out After: | 10,171,538 |
| Manager | Tier | Phone |
| Goldman, Sachs & Co. | Lead Manager | (212) 902-1172 |
| Bear, Stearns & Co. Inc. | Co-manager | (212) 272-2000 |
| Auditor: Price Waterhouse | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $0.07 | $0.06 | $0.00 | Assets: | $3.54 |
| Net Income: | -$2.50 | -$0.67 | -$0.56 | Liabilities: | $0.18 |
| EPS: | -$0.33 | -$0.08 | Equity: | $3.35 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, including proprietary disposable electrodes, the company is addressing such key problems in cardiac diagnosis as (i) the identification of those at risk of sudden cardiac death, accounting for of approximately 50% of all deaths due to heart attack, (ii) the early detection of coronary artery disease and (iii) the prompt and accurate diagnosis of heart attack. With the emergence of new preventive therapies for sudden cardiac death, the company believes that the accurate diagnosis of patients needing these therapies has become increasingly important. Existing non-invasive diagnostic tests generally either identify only a small subset of patients who are at risk of sudden cardiac death or are insufficiently accurate to warrant further invasive study or treatment. |
| Use of Proceeds |
| Proceeds from the offering will be used for research and development, clinical studies, capital equipment, sales and marketing, and for working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.